All resolutions concerning cardiovascular medicinal products

Dulaglutid (2, reassessment) Trulicity® Lilly Deutschland GmbH Metabolic diseases CV Diabetes mellitus type 2 31% Indication for minor additional benefit
Betibeglogene autotemcel (autologe hämatopoetische Stammzellen) Zynteglo® bluebird bio (Germany) GmbH Hematopoietic diseases CV ORPHAN β-thalassemia 100% Indication for non-quantifiable additional benefit
Turoctocog alfa pegol Esperoct® Novo Nordisk Pharma GmbH Hematopoietic diseases CV Hemophilia A 100% no additional benefit
Dapagliflozin / Metformin (3, reassessment) Xigduo® AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 50% Indication for minor additional benefit
Dapagliflozin (4, reassessment) Forxiga® AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 41% Indication for minor additional benefit
Empagliflozin / Linagliptin Glyxambi® Boehringer Ingelheim Pharma GmbH & Co. KG Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Dapagliflozin (3) Forxiga® AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 1 100% Indication for minor additional benefit
Emicizumab (2) Hemlibra® Roche Pharma AG Hematopoietic diseases CV Hemophilia A 100% no additional benefit
Damoctocog alfa pegol Jivi® Bayer Vital GmbH Hematopoietic diseases CV Hemophilia A 100% no additional benefit
Insulin degludec (4, reassessment) Tresiba® Novo Nordisk Pharma GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Alirocumab (2, reassessment) Praluent® Sanofi-Aventis Deutschland GmbH Metabolic diseases CV Hypercholesterolemia, Dyslipidemia 100% no additional benefit
Semaglutid Ozempic® Novo Nordisk Pharma GmbH Metabolic diseases CV Diabetes mellitus type 2 37% Indication for minor additional benefit
Sitagliptin (3, reassessment) Januvia® MSD Sharp & Dohme GmbH Metabolic diseases CV Diabetes mellitus type 2 100% Indication for minor additional benefit
Caplacizumab Cablivi® Sanofi-Aventis Deutschland GmbH Hematopoietic diseases CV ORPHAN Acquired thrombotic thrombocytopenic purpura (aTTP) 100% non-quantifiable additional benefit
Rurioctocog alfa pegol Adynovi® Shire Deutschland GmbH Hematopoietic diseases CV Hemophilia A 100% no additional benefit
Hydrocortison Alkindi® Diurnal Ltd. Metabolic diseases CV Adrenal insufficiency (Addison's disease) 100% no additional benefit
Ertugliflozin / Sitagliptin Steglujan® MSD Sharp & Dohme GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Emicizumab Hemlibra® Roche Pharma AG Hematopoietic diseases CV Hemophilia A 50% Indication for non-quantifiable additional benefit
Evolocumab (2, reassessment) Repatha® Amgen GmbH Metabolic diseases CV Hypercholesterolemia 100% no additional benefit
Insulin glargin / Lixisenatid Suliqua® Sanofi-Aventis Deutschland GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Dapagliflozin / Metformin (2, reassessment) Xigduo® AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Dapagliflozin (2, reassessment) Forxiga® AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Nonacog beta pegol Refixia® Novo Nordisk Pharma GmbH Hematopoietic diseases CV Hemophilia B 100% no additional benefit
Saxagliptin / Metformin (4) Komboglyze® AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Lonoctocog alfa Afstyla® CSL Behring GmbH Hematopoietic diseases CV Hemophilia A 100% no additional benefit
Macitentan (2, reassessment >€50m) Opsumit® Actelion Pharmaceuticals Deutschland GmbH Cardiovascular diseases CV ORPHAN Pulmonary hypertension (PHT) 100% no additional benefit
Sitagliptin / Metformin (2, reassessment) Janumet® MSD Sharp & Dohme GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Sitagliptin (2, reassessment) Januvia® MSD Sharp & Dohme GmbH Metabolic diseases CV Diabetes mellitus type 2 35% Indication for minor additional benefit
Saxagliptin / Metformin (3, reassessment) Komboglyze® AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Saxagliptin (2, reassessment) Onglyza® AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Selexipag Uptravi® Actelion Pharmaceuticals Deutschland GmbH Cardiovascular diseases CV Pulmonary hypertension (PHT) 100% no additional benefit
Eftrenonacog alfa Alprolix® Swedish Orphan Biovitrum GmbH Hematopoietic diseases CV ORPHAN Hemophilia B 100% non-quantifiable additional benefit
Albutrepenonacog alfa Idelvion® CSL Behring GmbH Hematopoietic diseases CV ORPHAN Hemophilia B 100% non-quantifiable additional benefit
Ticagrelor (2) Brilique® AstraZeneca GmbH Cardiovascular diseases CV Prevention of atherothrombotic events 100% Indication for minor additional benefit
Empagliflozin / Metformin Synjardy® Boehringer Ingelheim Pharma GmbH & Co. KG Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Empagliflozin (2, reassessment) Jardiance® Boehringer Ingelheim Pharma GmbH & Co. KG Metabolic diseases CV Diabetes mellitus type 2 42% Indication for considerable additional benefit
Sacubitril / Valsartan Entresto® Novartis Pharma GmbH Cardiovascular diseases CV Heart failure 68% Indication for considerable additional benefit
Efmoroctocog alfa Elocta® Swedish Orphan Biovitrum GmbH Hematopoietic diseases CV Hemophilia A 100% no additional benefit
Alirocumab Praluent® Sanofi-Aventis Deutschland GmbH Metabolic diseases CV Hypercholesterolemia 100% no additional benefit
Evolocumab Repatha® Amgen GmbH Metabolic diseases CV Hypercholesterolemia 100% no additional benefit
Insulin degludec / Liraglutid (2) Xultophy® Novo Nordisk Pharma GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Edoxaban Lixiana® Daiichi Sankyo Deutschland GmbH Cardiovascular diseases CV Venous thromboembolism / stroke prevention 81% Hint for minor additional benefit
Lomitapid (2, reassessment) Lojuxta® Aegerion Pharmaceuticals GmbH Metabolic diseases CV Hypercholesterolemia 100% no additional benefit
Insulin degludec / Liraglutid Xultophy® Novo Nordisk Pharma GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Insulin degludec (3) Tresiba® Novo Nordisk Pharma GmbH Metabolic diseases CV Diabetes mellitus 100% no additional benefit
Dulaglutid Trulicity® Lilly Deutschland GmbH Metabolic diseases CV Diabetes mellitus type 2 30% Indication for minor additional benefit
Vildagliptin (2, reassessment) Galvus® Novartis Pharma GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Simoctocog alfa Nuwiq® Octapharma GmbH Hematopoietic diseases CV Hemophilia A 100% no additional benefit
Albiglutid Eperzan® GlaxoSmithKline GmbH & Co. KG Metabolic diseases CV Diabetes mellitus type 2 35% Hint for minor additional benefit
Apixaban (3) Eliquis® Bristol-Myers Squibb GmbH & Co. KGaA / Pfizer Deutschland GmbH Cardiovascular diseases CV Venous thromboembolism 47% Hint for minor additional benefit
Empagliflozin Jardiance® Boehringer Ingelheim Pharma GmbH & Co. KG Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Canagliflozin / Metformin Vokanamet® Janssen-Cilag GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Insulin degludec (2) Tresiba® Novo Nordisk Pharma GmbH Metabolic diseases CV Diabetes mellitus 100% no additional benefit
Insulin degludec Tresiba® Novo Nordisk Pharma GmbH Metabolic diseases CV Diabetes mellitus 100% no additional benefit
Riociguat Adempas® Bayer Vital GmbH Cardiovascular diseases CV ORPHAN Pulmonary hypertension (PHT) 100% minor additional benefit
Canagliflozin Invokana® Janssen-Cilag GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Dapagliflozin / Metformin Xigduo® Bristol-Myers Squibb GmbH & Co. KGaA / AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Macitentan Opsumit® Actelion Pharmaceuticals Deutschland GmbH Cardiovascular diseases CV ORPHAN Pulmonary hypertension (PHT) 100% minor additional benefit
Turoctocog alfa NovoEight® Novo Nordisk Pharma GmbH Hematopoietic diseases CV Hemophilia A 100% no additional benefit
Lomitapid Lojuxta® Aegerion Pharmaceuticals GmbH Metabolic diseases CV Hypercholesterolemia 100% no additional benefit
Vildagliptin Galvus® Novartis Pharma GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Vildagliptin / Metformin Eucreas® Novartis Pharma GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Sitagliptin / Metformin Janumet® MSD Sharp & Dohme GmbH Metabolic diseases CV Diabetes mellitus type 2 78% Indication for minor additional benefit
Sitagliptin Januvia® MSD Sharp & Dohme GmbH Metabolic diseases CV Diabetes mellitus type 2 64% Indication for minor additional benefit
Saxagliptin / Metformin (2) Komboglyze® Bristol-Myers Squibb GmbH & Co. KGaA / AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Saxagliptin Onglyza® Bristol-Myers Squibb GmbH & Co. KGaA / AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 49% Indication for minor additional benefit
Lixisenatid Lyxumia® Sanofi-Aventis Deutschland GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Dapagliflozin Forxiga® Bristol-Myers Squibb GmbH & Co. KGaA / AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Linagliptin (3) Trajenta® Boehringer Ingelheim International GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Saxagliptin / Metformin Komboglyze® Bristol-Myers Squibb GmbH & Co. KGaA / AstraZeneca GmbH Metabolic diseases CV Diabetes mellitus type 2 85% Indication for minor additional benefit
Linagliptin (2, reassessment) Trajenta® Boehringer Ingelheim International GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Aliskiren / Amlodipin Rasilamlo® Novartis Pharma GmbH Cardiovascular diseases CV Hypertension 100% no additional benefit
Apixaban Eliquis® Bristol-Myers Squibb GmbH & Co. KGaA / Pfizer Deutschland GmbH Cardiovascular diseases CV Thromboembolism prevention 58% Hint for minor additional benefit
Apixaban (2) Eliquis® Bristol-Myers Squibb GmbH & Co. KGaA / Pfizer Deutschland GmbH Cardiovascular diseases CV Atrial fibrillation (AF) stroke prevention 100% Hint for minor additional benefit
Azilsartan Medoxomil Edarbi® Takeda Pharma GmbH Cardiovascular diseases CV Hypertension 100% no additional benefit
Ticagrelor Brilique® AstraZeneca GmbH Cardiovascular diseases CV NSTEMI/STEMI/stroke prevention 73% Proof of considerable additional benefit
Linagliptin Trajenta® Boehringer Ingelheim International GmbH Metabolic diseases CV Diabetes mellitus type 2 100% no additional benefit
Pitavastatin Livazo® Merckle Recordati GmbH Metabolic diseases CV Hypercholesterolemia 100% no additional benefit